Improving Lives Through
Diagnostic and
Therapeutic Solutions
AXIM’s proprietary research intends to find new ways to diagnose and treat cancer as well as other conditions through laboratory-derived cannabinoid and oncological therapeutics.
Improving Lives Through
Diagnostic and
Therapeutic Solutions
AXIM’s proprietary research intends to find new ways to diagnose and treat cancer as well as other conditions through laboratory-derived cannabinoid and oncological therapeutics.
COVID-19 TESTING
CLINICAL therapeutics
AXIM’s clinical therapeutic research focuses around an enzyme called “QSOX1” where the company hopes to bring a novel oncology drug to market
CANCER dIAGNOSTICS
AXIM is in development of various “point-of-care” diagnostic testing products designed for the early detection of cancer
The Latest On Our Research
Coronavirus company news summary – Color receives EUA for Covid-19 self-collection kit – Vivera Pharmaceuticals launches BIOZONE device
AXIM Biotechnologies has filed an Emergency Use Authorisation (EUA) application with the US Food and Drug Administration (FDA) for its first-in-class rapid diagnostic test for Covid-19. AXIM’s rapid diagnostic test is expected to be the market’s first Covid-19 rapid...
AXIM Biotechnologies files EUA with FDA for Covid-19 rapid diagnostic test for neutralising antibodies
AXIM’s rapid diagnostic test is expected to be the market’s first Covid-19 rapid diagnostic test for measuring levels of functional neutralising antibodies in a lateral flow assay format. AXIM Biotechnologies, an international healthcare solutions company targeting...
First-in-Class Rapid Diagnostic Test Measures COVID-19 Neutralizing Antibodies in Plasma and Serum
By HospiMedica International staff writers Posted on 17 Sep 2020 A new rapid diagnostic test is expected to be the market’s first COVID-19 rapid diagnostic test for measuring the levels of functional SARS-CoV-2 neutralizing antibodies in a lateral flow assay format....